Scott Burell is now chief financial officer of AIVITA Biomedical and Kevin Green is the company’s new vice president of business development.
AIVITA Biomedical is a biotech company specializing in stem cell applications, including ovarian cancer and glioblastoma. The company also manufactures two skincare lines, ROOT OF SKIN and ROOT OF SKIN MD, which include a proprietary actives complex containing the natural ingredients of skin stem cells.
Burell brings more than 25 years of corporate finance experience ranging from M&A to strategic management, operational management, financial reporting and compliance to the position. Prior to joining AIVITA, he served as CFO of CombiMatrix Corporation.
Green previously served as senior director of business development at Allergan for 10 years.
“Mr. Burell and Mr. Green bring decades of B2B, corporate finance and capital raising experience to AIVITA,” said Dr. Hans S. Keirstead, AIVITA’s chairman and CEO. “These appointments reflect our plans for further capitalization via investment and partnership.”
The company recently announced that the University of California, Irvine’s Comprehensive Brain Tumor Program and the UCLA-UCI Alpha Stem Cell Clinic have received IRB approval to begin recruiting patients with newly diagnosed glioblastoma for a phase 2 trial of AIVITA’s platform ROOT OF CANCER treatment.
The technology is also currently the subject of a Phase 2 clinical trial in ovarian cancer in the U.S. and a commercialization effort in melanoma in Japan.
